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Erythropoietin is produced by the kidney and stimulates
erythropoiesis; however, in chronic renal disease its levels are
reduced and patients develop anemia that is treatable with
iron and recombinant hormone. The mechanism by which
erythropoietin improves iron homeostasis is still unclear, but
it may involve suppression of the iron regulatory peptide
hepcidin and/or a direct effect on intestinal iron absorption.
To investigate these possibilities, we used the well-
established 5/6th nephrectomy rat model of chronic renal
failure with or without human recombinant erythropoietin
treatment. Monolayers of human intestinal Caco-2 cells were
also treated with erythropoietin to measure any direct effects
of this hormone on intestinal iron transport. Nephrectomy
increased hepatic hepcidin expression and decreased
intestinal iron absorption; these effects were restored to
levels found in sham-operated rats on erythropoietin
treatment of the rats with renal failure. In Caco-2 cells, the
addition of erythropoietin significantly increased the
expression of apical divalent metal transporter 1 (DMT1) and
basolateral ferroportin and, consequently, iron transport
across the monolayer. Taken together, our results show that
erythropoietin not only exerts a powerful inhibitory action on
the expression of hepcidin, thus permitting the release of
iron from reticuloendothelial macrophages and intestinal
enterocytes, but also acts directly on enterocytes to increase
iron absorption.
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Iron is essential for the maintenance of human health.
However, imbalances in iron homeostasis in humans are
relatively common. Iron deficiency anemia affects some 2
billion people (approximately one-third of the world’s
population) making it the most prevalent nutritional
deficiency disorder worldwide.1 In addition, anemia asso-
ciated with chronic disease and renal failure is common in
hospitalized patients.2 Studies in rodent models indicate that
the primary mechanism by which the body compensates for
imbalances in iron status occurs at the level of the intestinal
enterocyte. Duodenal iron absorption is altered dramatically
in response to changes in dietary iron composition,3,4 and by
factors that alter hematological parameters, for example,
hypoxia5 and hemolytic anemia.6,7
It is well known that anemia leads to tissue hypoxia, which
in turn stimulates the renal production of the glycoprotein
hormone erythropoietin (Epo).8 Relatively high levels of Epo
have been observed in patients with iron deficiency
anemia.9,10 In contrast, Epo levels are dramatically decreased
in patients with chronic renal failure (CRF);11 these patients
are treated with a combination of Epo and intravenous iron
to correct their anemia associated with CRF.11,12
The mode of action of Epo on iron metabolism is unclear.
In cell culture and animal studies, Epo has been shown to
decrease hepatic hepcidin expression,13–16 suggesting that the
effect of Epo on iron homeostasis could be mediated by
control of blood levels of this iron regulatory peptide.
Interestingly, in the absence of active erythropoiesis the
inhibitory effect of Epo on hepcidin expression is lost,
indicating that additional factors are required for the
erythropoietic regulation of hepcidin.17,18 Hepcidin is a
major regulator of body iron homeostasis and acts directly on
a number of cell types, in particular iron recycling
macrophages19–21 and intestinal epithelial cells,22–24 in which
it limits iron release into the circulation. Although it is
possible that the Epo–hepcidin axis is a major route for
controlling iron metabolism in CRF, it is also possible that
Epo can act directly on the intestinal epithelium to increase
dietary iron absorption. In this study, we have examined
these possibilities using both an in vivo rodent model of CRF
and a well-characterized in vitro enterocyte model. Our data
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show that Epo not only exerts a powerful inhibitory action
on the expression of hepcidin, but also acts directly on
enterocytes to increase iron absorption.
RESULTS
5/6th nephrectomy in rats induces CRF
Surgical resection and removal of renal tissue resulted in
doubling of serum creatinine (sham, 0.03±0.001mmol/l;
nephrectomy, 0.07±0.004mmol/l; Po0.05) and serum urea
(sham, 7.4±1.1mmol/l; nephrectomy, 14.2±1.2mmol/l;
Po0.01); both indices of CRF in animals and humans. All
animals gained weight over the experimental period and
there were no significant differences in animal weights among
any of the experimental groups (Supplementary Table S1).
Hematocrit (Hct) in nephrectomized animals was sig-
nificantly lower than in sham-operated controls (Table 1).
Epo treatment significantly increased Hct in both nephrec-
tomized and sham-operated animals. Serum iron levels were
not significantly different in nephrectomized and sham-
operated animals; furthermore serum iron levels were not
affected by Epo administration in either animal group. In
both the nephrectomy and sham-operated groups, Hct was
significantly increased by turpentine; Hct was further
increased by Epo treatment in turpentine-injected animals
(Table 1). In the nephrectomyþ turpentine group, serum
iron levels were significantly decreased; however, this was
normalized by Epo treatment.
Hepcidin expression
Previous studies have suggested that Epo elicits its effects on
body iron metabolism through an inhibitory action on
hepatic hepcidin expression. To test this hypothesis in our
CRF model, hepatic hepcidin mRNA expression was
measured in all treatment groups. There was a significant
increase in hepcidin mRNA expression in nephrectomized
rats compared with the sham-operated group (sham-
operated vs nephrectomized; Po0.002). Although Epo
treatment decreased hepcidin mRNA in nephrectomized
animals to levels observed in sham-operated controls, this
effect was not statistically significantly. There was no effect of
Epo treatment on hepcidin mRNA levels in sham-operated
rats. Treatment with turpentine significantly increased
hepcidin mRNA expression in both the sham-operated and
the nephrectomy groups. Administration of Epo to these
animals significantly decreased hepcidin mRNA levels in
nephrectomized animals, but not in the sham-operated
controls (Figure 1).
In vivo duodenal iron uptake
Hepcidin is a major regulator of body iron homeostasis and
has been shown to control intestinal iron absorption.25
Therefore, we analyzed whether the modulation of hepcidin
expression observed in our various treatment groups
might, in turn, influence dietary iron absorption (Figure 2).
Iron transport across the duodenal epithelium, and its
appearance in the circulation, was significantly decreased in
nephrectomized animals compared with sham-operated
controls (sham-operated vs nephrectomized; Po0.03 at
t¼ 10, 15, and 30min). After treatment of nephrectomized
animals with Epo, iron absorption was significantly in-
creased, reaching levels observed in the sham-operated
control animals. Epo treatment did not significantly influence
iron transport in the sham-operated group. In both
nephrectomized and sham-operated rats, the additional
inflammatory insult from turpentine significantly decreased
iron transport compared with the respective untreated
controls. Interestingly, while the addition of Epo decreased
hepcidin and increased Hct in turpentine-treated nephrecto-
mized rats, it did not significantly alter intestinal iron
absorption.
The duodenal expression of divalent metal transporter 1
(DMT1) and ferroportin was measured by western blotting
and real-time PCR. At the protein level, there were no
Table 1 | Blood iron parameters in experimental groups
Animal group Hb (g/dl) Hct (%)
Serum Fe
(lmol/l)
Sham operation 13.0±1.4a 44.8±0.8a 14.8±1.2a
Sham+Epo 15.1±0.5a 49.1±1.3c,d 15.4±2.0a
Sham+turpentine 13.4* 49.4±1.0c,d ND
Sham+turpentine+Epo 13.0±0.7a 56.7±1.2e ND
Nephrectomy 12.1±0.1a 39.8±0.6b 15.5±1.8a
Nephrectomy+Epo 17.1±0.7b 53.1±1.2d 12.9±1.1a
Nephrectomy +turpentine 12.2±0.3a 46.7±0.9a,c 3.3±0.6b
Nephrectomy+turpentine+Epo 14.4±1.1a 58.0±1.0e 13.6*
Abbreviations: Epo, erythropoietin; Hct, hematocrit; ND, not determined.
*Measured in one sample in this group. Data are means±s.e.m. of 3–6 observations
in each group. Groups with different letters are significantly different.
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Figure 1 |Hepatic hepcidin mRNA expression in
nephrectomized rats. RNA was isolated from livers of sham-
operated (S); nephrectomized (N); erythropoietin (Epo)-treated
(100U/kg body weight Epo; intraperitoneal (i.p.), twice weekly for
5 weeks) (Sþ E; Nþ E); turpentine-injected (0.1ml/20 g body
weight – 16 h before experimentation) (Sþ T; Nþ T); turpentine
and Epo-treated (Sþ Tþ E; Nþ Tþ E) rats, and used to measure
hepcidin mRNA. Data boxes show median (horizontal line) and
interquartile ranges. Vertical lines show the data range. There
were 4–6 observations in each group. Group data bars that do not
share common letters are significantly different from each other
(Uppercase¼ sham-operated animals; lowercase¼ nephrectomized
animals), Po0.05.
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significant differences in transporter expression among experi-
mental groups (Supplementary Table S2); however, at the
mRNA level both DMT1 and ferroportin were significantly
decreased in nephrectomized animals treated with turpentine
compared with all other experimental groups (Supplementary
Table S3).
Epo receptors are expressed in both rat enterocytes and
Caco-2 cells
The data obtained above were broadly consistent with the
hypothesis that an Epo–hepcidin axis regulates duodenal iron
absorption; however, a significant deviation from this
hypothesis was also evident. We therefore wanted to
determine whether Epo might also have direct effects on
the intestinal epithelium. Preliminary studies suggested that
this was a possibility, because Epo receptors are present in
both duodenal upper villus enterocytes and in Caco-2 cells,
which are a recognized model of human intestinal enter-
ocytes (Figure 3). Given the plethora of changes in circulating
factors that are associated with CRF, including elevations in
plasma levels of inflammatory cytokines and hepcidin and
decreased levels of Epo,26 we decided to use the Caco-2 cell
model to analyze further the potential effects of Epo on
intestinal iron metabolism.
Expression of iron transport genes in Caco-2 cells
Iron transport across the intestinal epithelium is mediated by
DMT1 and duodenal cytochrome b (Dcytb) at the apical
membrane, and ferroportin and hephaestin at the basolateral
surface of the cell.27 Preliminary studies showed that DMT1 and
ferroportin mRNA expression was increased by Epo in a dose-
dependent manner (Figure 4a). The lowest concentration of Epo
to elicit a significant increase in transporter mRNA expression
was 1U/ml, and so this concentration of the hormone was used
in all subsequent studies. Quantitative real-time PCR studies
revealed that in addition to DMT1 and ferroportin, Epo also
significantly induced hephaestin mRNA expression (Figure 4b).
Changes in transporter expression were only observed in cells
exposed to Epo for 24h; no effects were observed at earlier time
points. Interestingly, there was no effect of Epo on Dcytb mRNA
expression. Epo-induced changes in iron transporter protein
expression mirrored the mRNA studies, with significant increases
in DMT1, ferroportin, and hephaestin after 24-h exposure to the
hormone (Figure 4c). Protein levels of Dcytb and the house-
keeper protein actin were not altered by Epo treatment.
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Figure 2 | In vivo transepithelial iron transport. The duodenal lumen was filled with 200 mmmol/l 59Fe2þ and the transfer of 59Fe across
the duodenal mucosa and into the blood was measured over time. Sham-operated (S); nephrectomized (N); erythropoietin (Epo)-treated
(Sþ E; Nþ E); turpentine-injected (Sþ T; Nþ T); turpentine and Epo-treated (Sþ Tþ E; Nþ Tþ E) rats. Data are means and s.e.m. of 4–6
observations in each group. Group data bars that do not share common letters are significantly different from each other
(Uppercase¼ sham-operated animals; lowercase¼ nephrectomized animals), Po0.05.
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Figure 3 | Epo receptor expression. Crude membrane protein
fractions were prepared from rat duodenal enterocytes (DE) and
Caco-2 cells and subjected to western blotting. Blots were probed
with a commercially available anti-erythropoietin (Epo) receptor
antibody. A single band atB 69 kDa was observed in Caco-2 cells
and corresponds to the predicted molecular mass of the Epo
receptor. The 69 kDa band was also observed in rat DE together
with bands at approximately 50 and 35 kDa.
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Iron uptake by Caco-2 cells
To determine the effects of Epo on intestinal iron transport,
we measured the uptake and efflux of radio-labeled iron by
Caco-2 cells previously exposed to Epo for 24 h at their
basolateral surface. Consistent with the in vivo transport data
shown in Figure 2, both the uptake of iron from the apical
solution into Caco-2 cells (Figure 5a) and its subsequent
release into the basolateral medium (Figure 5b) were signifi-
cantly increased in the Epo-treated cells. We have shown
previously28 that iron transport reaches steady-state equilibrium
within 1h. Net flux of iron across the Caco-2 cell monolayer
occurred in the apical to basal direction; transport of iron from
basal to apical under steady-state conditions (4.8±2.4 pmol/
cm2/h) was approximately 500- to 1000-fold lower.
Cell signaling pathways mediating the Epo response
The Epo receptor is functionally coupled to the non-receptor
tyrosine kinase Janus kinase 2 (JAK2),29,30 which once recruited
can activate a number of other cell signaling pathways. We
analyzed the effects of a JAK2 inhibitor (1,2,3,4,5,6-hexabro-
mocyclohexane) on basal and Epo-induced DMT1 and
ferroportin mRNA levels. Expression of both transporters
was induced by Epo (Figure 6a and b). Pre-incubation of Caco-
2 cells with 1,2,3,4,5,6-hexabromocyclohexane blocked the
induction of both DMT1 (Figure 6a) and ferroportin (Figure
6b) in Epo-treated cells, but it had no effect on basal
transporter expression levels. Similarly, transepithelial
iron transport across Caco-2 cell monolayers was decreased
by 1,2,3,4,5,6-hexabromocyclohexane in Epo-treated cells
(42.3±14.1%), but not in control cells (3.8±1.2%).
0
1
2
3
Epo concentration (U/ml)
Tr
an
sp
or
te
r m
RN
A 
(a.
u.)
DMT1
FPN
a
ab b
ab
A AB
B
B
0
1
2
3
4
N
or
m
al
iz
ed
 m
RN
A/
18
S 
ra
tio
 Untreated
4 h Epo
24 h Epo
b
a
a
b
a a
b
a
a
DMT1
Dcytb
FPN
Hp
Actin 0
0.4
0.8
1.2
1.6
2
Pr
ot
ei
n 
ex
pr
es
sio
n 
(a.
u.)
Untreated
4 h Epo
24 h Epo
+ Epo
b
a
ab
b
a
ab
b
a
ab
0 310.3
DMT1 HpFPNDcytb
UT 24 h4 h
DMT1 HpFPNDcytb
Figure 4 | Iron transporter expression in Caco-2 cells treated
with erythropoietin (Epo). (a) Divalent metal transporter 1
(DMT1) and ferroportin (FPN) mRNA expression were increased by
Epo in a dose-dependent manner. Quantitative PCR and western
blotting respectively revealed that mRNA (b) and protein
(c) expression of DMT1, ferroportin (FPN) and hephaestin (Hp)
were significantly increased in Caco-2 cells after 24 h exposure to
Epo (1 U/ml). There was no effect of Epo on duodenal cytochrome
b (Dcytb) expression. Representative blots for each iron transport
protein together with the housekeeper protein actin are shown.
Data are means and s.e.m. of eight observations in each group.
Means without common letters differ, Po0.05.
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Figure 5 | Iron transport in Caco-2 cells treated with
erythropoietin (Epo). Caco-2 cells were exposed to Epo (1 U/ml
added to the basolateral medium) for 24 h. Iron uptake across the
apical membrane of Caco-2 cell monolayers (a) and the release of
iron across the basolateral membrane into the basolateral
medium (b) were both significantly increased after Epo treatment.
Data are means and s.e.m. of 12 observations in each group.
*Po0.02; **Po0.001.
Kidney International (2010) 78, 660–667 663
SK Srai et al.: Epo and intestinal iron transport o r ig ina l a r t i c l e
DISCUSSION
CRF in humans is commonly associated with the develop-
ment of a normochromic normocytic anemia, although iron
stores are also often low. Oral iron is usually ineffective and
the anemia of CRF requires treatment with intravenous iron,
to replenish iron stores, and injectable Epo. However,
measures of adequate iron reserves such as ferritin (which
is an acute-phase protein) can be misleading, and there are
still concerns over the regular use of parenteral iron in
patients with CRF and the risks of iron overload and
toxicity.31–33 For these reasons we have used an animal model
of CRF to analyze the regulation of intestinal iron transport
before and after treatment with Epo. As in patients with renal
failure, CRF (i.e., 5/6th nephrectomy) animals show a
significantly reduced Hct that is sensitive to Epo treatment.
Hepcidin is recognized as a major regulator of body iron
metabolism and acts by limiting iron release from a number
of cells and tissues, including duodenal enterocytes22,23 and
reticuloendothelial macrophages.19–21 In human CRF patients
hepcidin levels are elevated,26,34,35 which may be the result of
decreased Epo levels, because addition of Epo has been
shown to downregulate hepcidin in a number of experi-
mental models.13–16 In this study, we found that hepcidin was
significantly elevated in our 5/6th nephrectomy model of
CRF, and that this was associated with a significant decrease
in duodenal iron transport. Treatment of nephrectomized
rats with Epo reversed these effects, resulting in a non-
significant decrease in hepcidin expression, but a significant
increase in duodenal iron transport to levels observed in the
sham-operated group. Epo treatment also increased Hct and
hemoglobin levels in nephrectomized animals, but it did not
influence serum iron levels. Sham-operated animals treated
with Epo also had a significantly increased Hct, but no
significant difference in serum iron levels compared with
untreated controls. These are important observations because
they confirm that the effects of Epo on duodenal iron
transport in nephrectomized rats are likely to be primary
regulatory events and not secondary to Epo-induced iron
deficiency. Furthermore, these data indicate that other
circulating factors released in response to increased erythro-
poietic drive may also contribute to the regulation of iron
homeostasis in vivo. This possibility is supported by
published data showing that in the absence of active
erythropoiesis, the inhibitory effect of Epo on hepcidin
expression is lost.17,18
The increase in hepcidin expression in CRF may arise
from the increase in circulating levels of inflammatory
cytokines in this condition, which may serve to stimulate
hepcidin production.36–38 In our animal models, we
administered turpentine subcutaneously to produce an
inflammatory response. In both sham-operated and ne-
phrectomized rats this treatment significantly increased
hepatic hepcidin expression and significantly decreased
duodenal iron transport. Interestingly, while administration
of Epo to the nephrectomyþ turpentine group significantly
reduced hepcidin expression, duodenal iron transport
remained significantly suppressed. These data are consistent
with recent observations from our own group, and from
others, that whereas hepcidin levels are closely associated
with macrophage ferroportin expression,19–21,25 iron re-
lease,19 and subsequent changes in serum iron levels,21,25,39
intestinal enterocytes are less sensitive to changes in
hepcidin.21,25 This suggests that additional factors, for
example, pro-inflammatory cytokines released as a result of
the turpentine injection, exert a powerful negative influence
on the intestinal iron transport pathway.
Although the inhibitory actions of hepcidin21,23,25 and
pro-inflammatory cytokines such as tumor necrosis factor
a40–42 on intestinal iron transport have been characterized,
there is little information on the direct effect of Epo on the
transfer of iron across the intestinal mucosa. There are
studies in the literature suggesting that Epo receptors are
present on rat and human small intestinal enterocytes.43,44
The membrane localization of these receptors is unclear but
there is evidence for expression on both the apical and
basolateral surfaces. In the context of our study, Epo would
only be able to act on receptors on the basolateral membrane
of enterocytes. In this study, we have confirmed abundant
levels of Epo receptor protein on rat duodenal enterocytes
and we have detected them on human intestinal Caco-2 cells.
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This raises the possibility that in the context of renal failure,
administration of Epo may also act directly on intestinal
enterocytes to regulate dietary iron absorption. Furthermore,
there is evidence for an increase in iron absorption in normal
subjects after Epo administration.45
It is difficult to distinguish experimentally between the
separate effects of Epo, hepcidin, cytokines, and other
confounding factors on iron transport in the context of iron
homeostasis in vivo. In addition, isolated enterocytes are not
suitable for studying vectorial iron transport, as they rapidly
lose viability and polarity once removed from the villus.46
Therefore, we used Caco-2 cells to analyzed whether Epo
directly influenced intestinal epithelial iron transport. After
treatment with Epo (24 h), there was a significant increase in
iron uptake across the apical membrane of the Caco-2 cell
monolayer. This was associated with an increase in both the
mRNA and protein expression of the apical membrane iron
transporter DMT1. Interestingly, there was no effect of Epo on
the expression of the apical membrane resident ferric reductase
Dcytb; however, this may reflect the very low levels of
expression of this gene in the Caco-2 cell line.47 Epo treatment
also resulted in a significant increase in iron efflux across the
basolateral membrane of Caco-2 cells into the serosal medium.
There was significant upregulation of protein and mRNA
levels of both the ferroportin transporter and the ferrioxidase
hephaestin, consistent with this increase in iron efflux.
The Epo receptor is functionally coupled to the tyrosine
kinase JAK229,30 that can activate a number of downstream
signaling events. We were able to block the Epo-induced
increases in both DMT1 and ferroportin mRNA expression,
and transepithelial iron transport using a JAK2 inhibitor,
indicating that the effects of Epo on iron metabolism in Caco-2
cells are directly mediated through Epo receptor signaling.
Thus, our data provide evidence for a direct effect of Epo
on the intestinal handling of iron. Taken together with the
actions of Epo on iron homeostasis in other non-hemato-
poietic tissues such as hepatocytes,14,16 our studies support
an expanding role for Epo in regulating body iron
metabolism. In the context of treating anemia in CRF, Epo
enhances the rate of erythropoiesis and downregulates
hepcidin, which in turn permits the release of iron from
reticuloendothelial macrophages; in addition, Epo also
stimulates intestinal iron absorption directly. Together, these
pathways can normalize iron balance. Epo clearly exerts
several different actions to maintain iron homeostasis;
elucidating the cellular signaling pathways underlying these
mechanisms could provide new selective and individualized
therapeutic targets for the treatment of anemia and could
avoid inappropriate or excessive use of iron supplements.
MATERIALS AND METHODS
Animals
The surgical procedure for inducing CRF has been described in
detail elsewhere.48 Briefly, male Sprague–Dawley rats (230 g) under-
went a two-stage 5/6-nephrectomy or a sham operation. Animals
were anesthetized using 2–3% halothane in 100% oxygen. The left
kidney was exposed, the renal pedicle was temporarily clamped, and
7/8 of the cortex resected (equivalent to two-thirds of the single
kidney mass). The remnant kidney was then wrapped in Surgicel
(Ethicon, Livingston, UK) and the clamp removed. One week later,
again under halothane anesthesia, the right kidney was removed and
the same recovery procedure used. For the sham operation, the same
procedures were carried out and the kidney was gently manipulated.
After surgery, animals were allowed ad libitum access to water and
standard rat chow (diet RM1—180mgFe/kg, SDS, Witham, Essex,
UK). For the final 4 weeks before experimentation, animals were fed
an iron-deficient diet (0.5mg Fe/kg diet). All animals were weighed
at the start and end of the experimental period to determine
whether there were any changes in their growth.
Some animals were subsequently treated with either Epo (100U/kg
body weight recombinant human Epo; Roche, Welwyn Garden City,
Herts, UK), twice weekly intraperitoneal injections for 5 weeks;
turpentine (0.1ml/20 g body weight), administered subcutaneously
16 h before experimentation; or both Epo and turpentine. Untreated
sham-operated and nephrectomized animals received equal volumes
of 0.9% saline via the appropriate route. The concentration of Epo
used in these studies (100U/kg body weight) is consistent with those
used in human CRF patients.33
All procedures were carried out in accordance with current UK
Home Office guidelines and local ethics committee regulations.
In vivo iron uptake
Rats were anesthetized with pentobarbitone sodium (60mg/kg body
weight, intraperitoneal). The duodenum (a 5 cm section starting
immediately distal to the pylorus) was rinsed free of its lumenal
contents and filled with uptake buffer (Hepes-buffered saline
containing 200 mmmol/l 59Fe2þ : 4mmol/l ascorbate; pH 6.5). Blood
samples were removed via a femoral cannula over the next 30min to
measure the appearance of radio-labeled iron in the blood. At the
end of the experimental period, the duodenal segment was removed
and flushed thoroughly (with buffer containing 2mmol/l unlabeled
iron, followed by 0.15mol/l NaCl) before being dried overnight. The
mucosa and blood samples were weighed and g-counted to
determine 59Fe activity.
A further blood sample was taken at the end of each experiment
to measure Hct and hemoglobin levels, and plasma urea and
creatinine as measures of the degree of renal failure.
Cell culture
Caco-2 cells were grown in Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum for 14 days on Transwell inserts
(Corning–Costar, High Wycombe, UK). For experiments, cells were
placed in serum-free medium. Human recombinant Epo (1U/ml)
was added to the basolateral medium and cells were incubated for
up to 24 h. In some experiments, cells were incubated with the JAK2
inhibitor 1,2,3,4,5,6-hexabromocyclohexane (50 mmol/l) for 2 h
before exposure to Epo.
In vitro iron uptake
After exposure to Epo, Caco-2 cells were washed with phosphate-
buffered saline. Iron uptake was measured using the techniques
described in detail elsewhere.28 Briefly, a transepithelial pH gradient
was established by adding Mes-buffered saline (pH 5.5; 140mmol/l
NaCl, 5mmol/l KCl, 1mmol/l Na2HPO4, 1mmol/l CaCl2, 0.5mmol/
l MgCl2, 5mmol/l glucose, and 10mmol/l Mes) containing
10 mmol/l 59FeCl3 complexed with 1mmol/l ascorbic acid to the
apical well (reverse flux of iron was measured by adding the isotope
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to the basolateral medium) of the Transwell plate and adding
Hepes-buffered saline (pH 7.5; same ionic composition but
containing 10mmol/l Hepes in place of Mes and 0.2% bovine
serum albumin) to the basolateral chamber. After 1 h, the cells were
washed thoroughly and solubilized in 0.2mmol/l NaOH. The
solubilized cell fraction and aliquots of the basolateral medium were
subjected to g counting to determine the effects of Epo on iron
uptake and efflux respectively.
Quantitative PCR
Total RNA was isolated from rat liver and duodenal mucosa, and
from Caco-2 cells using Trizol reagent (Invitrogen, Paisley, UK)
according to the manufacturer’s instructions. After first-strand
cDNA synthesis, expression levels of hepcidin and actin in rat liver;
DMT1, ferroportin, and actin in rat duodenum; and DMT1, Dcytb,
ferroportin, hephaestin, and 18S mRNA in Caco-2 cells were
analyzed by real-time PCR using either a Roche Lightcycler (Roche
Diagnostics, Penzberg, Germany; rat samples) or an ABI Prism
7000HT PCR cycler (Applied Biosystems, Carlsbad, CA, USA;
Caco-2 cell samples) and a Quanti-Tect SYBR Green PCR kit
(Qiagen, West Sussex, UK) according to the manufacturer’s
protocol. The primer sequences used for PCR reactions are shown
in Supplementary Table S4. Quantitative measurement of each gene
was derived from a standard curve constructed from known
concentrations of PCR product and data are expressed normalized
to the housekeeper gene.
Western blotting
Total plasma membrane fractions from duodenal mucosal scrapings
and Caco-2 cells were prepared as described previously.21,49 Briefly,
mucosae and cultured cells were homogenized in phosphate-
buffered saline containing protease inhibitor cocktail (Sigma–
Aldrich, Dorset, UK) with an Ultra Turrax homogenizer (2 30 s
pulses on full speed). After precipitation of unbroken cells and
nuclei by centrifugation, the resulting supernatant was centrifuged
for 30min at 18,000 g to give a total plasma membrane fraction,
which was resuspended in phosphate-buffered saline, containing
protease inhibitor cocktail (10 mg/ml), 1% sodium dodecyl sulfate.
In studies to measure Epo receptor expression, duodenal upper
villus enterocytes were isolated using a well-characterized calcium
chelation technique50 and plasma membrane fractions prepared
using the same methodology as for Caco-2 cells.21,49
Membranes (40mg) were solubilized in sample loading buffer and
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis. After transfer onto nitrocellulose, the immobilized proteins were
exposed to commercially available antibodies to DMT1, Dcytb,
ferroportin, and hephaestin (1:1000 dilution, Alpha Diagnostics, San
Antonio, TX, USA) and Epo receptor (1:1000 dilution, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Reactivity was detected
using an horseradish peroxidase-linked secondary antibody (Dako,
Cambridgeshire, UK) and ECL Plus (GE Healthcare, Buckingham-
shire UK). Band densities were semi-quantified using Scion Image
software (Scion Corporation, Frederick, MD, USA). At the end of the
experiment, the nitrocellulose membranes were stripped (Western
Stripping Buffer, Perbio Science, Northumberland, UK) and re-
probed with an anti-actin antibody (1:2000 dilution, Sigma–Aldrich),
which acted as a loading control.
Statistical analysis
Data are presented as mean±s.e.m. Statistical differences (Po0.05)
between multiple groups were calculated using either a one-way
analysis of variance followed by Tukey’s post hoc test, or (for
non-parametric data) a Kruskal–Wallis test followed by a Mann–
Whitney U-test using a Bonferroni correction (Po0.05/n groups).
In studies containing only two experimental groups, Student’s
unpaired t-test was used to compare means (*Po0.05).
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